Related Experiment Video
Updated: May 25, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
Pediatric obesity: looking into treatment
Angelo Pietrobelli1, Simone Rugolotto, Paolo De Cristofaro
1Pediatric Unit, Verona University Medical School, Verona, 37134, Italy. angpie@tin.it
Nutrients
|January 19, 2012
Summary
Pediatric obesity is a growing global concern. Early identification and multidisciplinary treatment strategies are crucial for managing childhood obesity and its associated health risks.
Area of Science:
- Pediatrics
- Public Health
- Endocrinology
Background:
- Global prevalence of pediatric obesity is increasing.
- Obesity in children is linked to severe cardiovascular and metabolic complications.
- Early identification and intervention are critical for managing obesity-related diseases.
Purpose of the Study:
- To review current information on pediatric obesity treatment applicable to primary care.
- To examine eating and sedentary behaviors in pediatric obesity.
- To discuss multidisciplinary, behavior-based, and aggressive treatment options.
Main Methods:
- Review of current literature on pediatric obesity treatment.
- Analysis of eating and sedentary behaviors.
- Evaluation of multidisciplinary, behavior-based, medication, and surgical interventions.
Main Results:
- Multidisciplinary, behavior-based programs show promise for treating pediatric obesity.
- Medication and bariatric surgery are options for severe or aggressive cases.
- Primary care providers can significantly impact outcomes through early identification and guidance.
Conclusions:
- Healthcare providers play a vital role in early identification and management of pediatric obesity.
- Structured guidance and support for families are essential for successful treatment.
- Comprehensive, multidisciplinary approaches are necessary for effective pediatric obesity care.
Related Concept Videos
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...